載入中
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.
一般交易時段
US$1.45
+US$0.02 · +1.40%
盤中時間採用ET。市場資料可能有所延遲。
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.
日內區間
目前US$1.45
52週區間
目前US$1.45
盤中時間採用ET。市場資料可能有所延遲。
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.
日內區間
目前US$1.45
52週區間
目前US$1.45
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 2186.61萬 USD | 353.09萬 USD | 172.81萬 USD | 806.96萬 USD | 1079.57萬 USD |
| 銷售、一般及管理費用 | 610.24萬 USD | 869.63萬 USD | 371.88萬 USD | 424.57萬 USD | 484.53萬 USD |
| 營業費用 | 2796.84萬 USD | 1222.72萬 USD | 544.69萬 USD | 1231.53萬 USD | 1564.09萬 USD |
| 利息收入 | 9.69萬 USD | — | 15.09萬 USD | 6.75萬 USD | 5672 USD |
| 利息支出 | — | 9.22萬 USD | — | — | — |
| 折舊和攤銷 | 2063 USD | 1.22萬 USD | — | — | — |
| 營業利益 | −2796.84萬 USD | −1222.72萬 USD | −544.69萬 USD | −1231.53萬 USD | −1564.09萬 USD |
| 淨利 | −3425.74萬 USD | −1234.97萬 USD | −529.6萬 USD | −1224.78萬 USD | −1596.03萬 USD |
公司資料更新於 2026年10月8日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
